Skip to main content
. Author manuscript; available in PMC: 2014 Dec 17.
Published in final edited form as: Sci Transl Med. 2014 May 14;6(236):236re4. doi: 10.1126/scitranslmed.3008169

Fig. 2. Citalopram reduces amyloid plaque formation and growth in APP/PS1 mice.

Fig. 2

Six month-old APP/PS1 mice were treated with Citalopram 10mg/kg per day or vehicle i.p. for 28d (Vehicle: n=6 mice, 49 plaques; Citalopram: n=8 mice, 116 plaques) and imaged using 2 photon microscopy. (A) Representative multiphoton micrographs of individual amyloid plaques in the cortex of APP/PS1 mice before (0d) and 28 days after treatment. A repeated measures ANOVA indicated that Citalopram attenuated the growth of pre-existing plaques. P: plaque; CAA: cerebral amyloid angiopathy; New P: newly appearing plaque. (B) Analysis using a cumulative logit model demonstrated that Citalopram reduced the likelihood of plaque growth, but did not induce plaque regression (C) Citalopram also reduced the appearance of new plaques based on comparison using a Wilcoxon rank-sum test (D), and inhibited CAA progression, based on a comparison using a t-test (E) during the 28 days of treatment compared to vehicle control. Scale bar, 50 μM; *P < 0.05; ** P < 0.01, ***P<0.001, **** P < 0.001 for Odds Ratio. Values represent mean ± SE.